SCHEMBL18254995

SCHEMBL18254995

Cc1ccccc1CN1CCC2=C(C1)C(=O)N(Cc1ccccc1Cl)C1=NCCN12

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLPP Q16740 7/20 0.82
▸ CYP3A4 P08684 3/20 0.82
▸ GPR132 Q9UNW8 2/20 0.82
▸ CYP2D6 P10635 2/20 0.82
▸ DRD3 P35462 2/20 0.82
▸ KCNH2 Q12809 2/20 0.82
▸ DRD2 P14416 1/20 0.82
▸ SMN1; SMN2 Q16637 2/20 0.72
▸ HIF1A Q16665 1/20 0.72
▸ HDAC1 Q13547 4/20 0.64
▸ HDAC3 O15379 1/20 0.52
▸ HDAC2 Q92769 1/20 0.52
▸ NCOR2 Q9Y618 1/20 0.52
▸ P2RX7 Q99572 2/20 0.41
▸ CYP2C19 P33261 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ ABCB11 O95342 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18255101 1.00 CLPP (0.82) CLPPCYP3A4GPR132CYP2D6DRD3
SCHEMBL18254991 0.94 CLPP (0.89) CLPPCYP3A4GPR132CYP2D6DRD3
SCHEMBL18254983 0.94 CLPP (0.72) CLPPCYP3A4GPR132CYP2D6DRD3
Dordaviprone SCHEMBL16227974 0.90 CLPP (1.00) CLPPCYP3A4GPR132CYP2D6DRD3
Dordaviprone SCHEMBL29359574 0.90 CLPP (1.00) CLPPCYP3A4GPR132CYP2D6DRD3
Dordaviprone SCHEMBL29414943 0.90 CLPP (0.98) CLPPCYP3A4GPR132CYP2D6DRD3
Dordaviprone SCHEMBL31548590 0.90 CLPP (0.98) CLPPCYP3A4GPR132CYP2D6DRD3
SCHEMBL18254980 0.89 CLPP (0.79) CLPPCYP3A4GPR132CYP2D6DRD3
SCHEMBL29595454 0.89 CLPP (0.79) CLPPCYP3A4GPR132CYP2D6DRD3
SCHEMBL18254989 0.89 CLPP (0.79) CLPPCYP3A4GPR132CYP2D6DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180141946-A1 Imidazo-pyrimidone Compounds, and Preparation Method and Application Thereof Madera Therapeutics, LLC 2018-05-24 — — US disclosed
US-20180141946-A1 Imidazo-pyrimidone Compounds, and Preparation Method and Application Thereof Madera Therapeutics, LLC 2018-05-24 — — US disclosed
EP-3315498-A1 IMIDAZO-PYRIMIDONE COMPOUNDS, AND PREPARATION METHOD AND APPLICATION THEREOF Nanjing Gator Meditech Company, Ltd. (CN) 2018-05-02 — — EP disclosed
WO-2016184437-A1 IMIDAZO-PYRIMIDONE COMPOUNDS, AND PREPARATION METHOD AND APPLICATION THEREOF 南京盖特医药技术有限公司 2016-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141946-A1 Imidazo-pyrimidone Compounds, and Preparation Method and Application Thereof TNFRSF1A, TNF, TNFRSF9 CLPP 1046/4885CYP3A4 858/4885GPR132 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback